Department of Radiation Oncology, University of Louisville, Louisville, Kentucky.
Department of Bioinformatics and Biostatistics, University of Louisville, Louisville, Kentucky.
Cancer. 2017 Sep 1;123(17):3277-3284. doi: 10.1002/cncr.30730. Epub 2017 Apr 27.
The objectives of this study were to characterize patterns of care and to identify predictors for adjuvant therapy in elderly patients with glioblastoma in the modern era.
The National Cancer Data Base was queried for patients aged 70 years and older with glioblastoma diagnosed from January 1, 2004 through December 31, 2012. Multinomial logistic regression was used to identify predictors for receiving adjuvant therapy. Survival outcomes were estimated using the Kaplan-Meier method and were analyzed using Cox regression models and the log-rank test.
In total, 14,886 patients were identified. Of these, 8214 patients (55.2%) received combined-modality therapy with chemotherapy and radiation (CRT), 3955 (26.6%) received no adjuvant therapy, 2065 (13.9%) received radiation therapy (RT) alone, and 652 (4.4%) received chemotherapy (CT) alone after undergoing resection. The receipt of CRT increased in frequency over the study interval, from 40.3% in 2004 to 59.8% in 2012. Younger patients (ages 70-75 years) were more likely to receive CRT than no adjuvant therapy (P < .0001 for all other age groups) or adjuvant RT alone (P < .0001 for all other age groups). Combined-modality therapy with adjuvant CRT produced improved survival outcomes, and the highest median overall survival was 9.2 months.
In this analysis of elderly patients who had glioblastoma diagnosed from 2004 through 2012, a significant increase in the receipt of combined-modality therapy was observed. Combined-modality treatment produces improved survival outcomes and should be considered as adjuvant treatment for carefully selected elderly patients. Cancer 2017;123:3277-84. © 2017 American Cancer Society.
本研究的目的是描述老年胶质母细胞瘤患者的治疗模式,并确定辅助治疗的预测因素。
从 2004 年 1 月 1 日至 2012 年 12 月 31 日,国家癌症数据库中检索出 70 岁及以上诊断为胶质母细胞瘤的患者。采用多项逻辑回归分析来确定接受辅助治疗的预测因素。使用 Kaplan-Meier 法估计生存结果,并使用 Cox 回归模型和对数秩检验进行分析。
共纳入 14886 例患者。其中,8214 例(55.2%)接受联合放化疗(CRT),3955 例(26.6%)未接受辅助治疗,2065 例(13.9%)接受单纯放疗(RT),652 例(4.4%)接受单纯化疗(CT)。在研究期间,CRT 的使用率逐渐升高,从 2004 年的 40.3%上升至 2012 年的 59.8%。年龄较轻的患者(70-75 岁)比未接受辅助治疗(所有其他年龄组均<.0001)或单纯接受辅助 RT (所有其他年龄组均<.0001)更有可能接受 CRT。辅助 CRT 的联合治疗可改善生存结局,中位总生存时间最长为 9.2 个月。
本研究分析了 2004 年至 2012 年间诊断为胶质母细胞瘤的老年患者,发现联合治疗的使用率显著增加。联合治疗可改善生存结局,应作为精心挑选的老年患者的辅助治疗方法。癌症 2017;123:3277-84。©2017 美国癌症协会。